Iterum Therapeutics plc (ITRM)

Iterum Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-35.58	-38.37	-44.43	-91.56	-52.01	-103.13
Depreciation & Amortization	1.32	1.75	1.8	2.1	0.16	0.15
Share-Based Compensation	0.53	0.78	4.76	4.32	2.76	2.17
Other Operating Activities	-9.09	-3.49	19.4	69.3	-5.44	18.88
Operating Cash Flow	-42.82	-39.33	-18.47	-15.84	-54.53	-81.92
Capital Expenditures	-0.01	-0.01	-0.06	-0.06	-0.01	-0.02
Change in Investments	25.45	23.35	14.02	-54.53	0	40.13
Investing Cash Flow	25.44	23.34	13.96	-54.6	-0.01	40.1
Share Issuance / Repurchase	8.02	1.03	0.43	89.64	69.96	3.1
Debt Issued / Paid	0	0	-2.25	-6.52	-5.49	-1.03
Financing Cash Flow	8.02	1.03	-1.82	83.13	64.48	2.06
Exchange Rate Effect	-0.08	-0.06	-0.05	0	-0.01	-0.02
Net Cash Flow	-9.44	-15.02	-6.38	12.69	9.93	-39.78
Free Cash Flow	-42.84	-39.34	-18.54	-15.9	-54.54	-81.95
Free Cash Flow Margin	-	-	-	-	-	-221475.68%
Free Cash Flow Per Share	-2.78	-3.04	-1.51	-1.46	-34.07	-84.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).